Articles from Agno Pharma

Agno Pharma Acquires Actylis’s CDMO Manufacturing Asset, the Legacy Cascade Chemistry Business based in Eugene, Oregon, Strengthening Agno’s US cGMP API Development and Manufacturing Capabilities
Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.
By Agno Pharma · Via Business Wire · January 15, 2026
Global CDMO Agno Pharma Completes Acquisition of Particle Sciences Inc.
Agno Pharma (“Agno”), a US-based, global pharmaceutical contract development and manufacturing organization, announced today that it will acquire the Lubrizol Particle Sciences Inc. business (“Particle Sciences”). The acquisition includes the drug product formulation technology behind the Particle Sciences Inc. business as well as the Bethlehem, PA, development and manufacturing site with approximately 65 employees.
By Agno Pharma · Via Business Wire · December 18, 2023